Bukwang Pharmaceutical financials at a glance

+ Portfolio

The revenue of Bukwang Pharmaceutical is reported as 142.13209 billion Won in the fiscal year 2023. The earnings were 389 Won per share in 2023, which was 0 higher than 2015. And about 7.46288 billion Won are reported as free cash flow in the financials of Bukwang Pharmaceutical 2023. No dividends were paid to the shareholders of the Bukwang Pharmaceutical stock KOSE:A003000 in the financial year 2023.

₩142.13B

Revenue

₩389.00

Earnings Per Share

37.26%

Gross Margin %

₩0.00M

Free Cash Flow

Revenue

142,132.09

Earnings Per Share

389.00

Gross Margin %

37.26

Free Cash Flow

0.00

Financials

Year	Year	TTM	2023	2015	2012
Rev.	Revenue	N/A	₩142.13B	₩142.13B	₩0.00M
GM %	Gross Margin %	40.59%	37.26%	58.04%	53.95%
OM	Operating Margin	-11.17%	-29.78%	16.38%	14.53%
EPS	Earnings Per Share	₩-,290.04	₩389.00	₩389.00	₩245.82
Div.	Dividends	N/A	₩294.32	₩294.32	₩0.00
PR %	Payout Ratio %	0	75.66%	75.66%	0
Sha.	Shares	N/AM	68.45M	64.59M	55.06M
OCF	Operating Cash Flow	N/A	₩10.30B	₩10.30B	₩0.00M
FCF	Free Cash Flow	N/A	₩7.46B	₩5.72B	₩0.00M
FCFS	Free Cash Flow Per Share	₩-40.93	₩-,174.26	₩94.90	₩700.40

Bukwang Pharmaceutical financials at a glance

Financials

Discover